Composite asthma endpoint: Asthma exacerbation (broad) with pneumonia plus asthma worsening
| Composite end point MedDRA preferred terms | Patients, n (%) | ||
|---|---|---|---|
| Tiotropium Respimat® 5 µg QD (n = 31) | Tiotropium Respimat® 2.5 µg QD (n = 36) | Placebo Respimat®
QD (n = 34) | |
| Asthma exacerbation (broad)/worsening + pneumonia | 9 (29.0) | 12 (33.3) | 19 (55.9) |
| Asthma | 2 (6.5) | 5 (13.9) | 10 (29.4) |
| Bronchitis | 2 (6.5) | 1 (2.8) | 4 (11.8) |
| Bronchopneumonia | 0 | 0 | 1 (2.9) |
| Cough | 2 (6.5) | 4 (11.1) | 3 (8.8) |
| Dyspnoea | 1 (3.2) | 0 | 0 |
| Pneumonia | 0 | 1 (2.8) | 2 (5.9) |
| Viral respiratory tract infection | 3 (9.7) | 3 (8.3) | 4 (11.8) |
| Wheezing | 0 | 2 (5.6) | 0 |
Treated set. Percentages calculated using total number of patients per treatment as denominator. AE preferred terms defined by Medical Dictionary for Regulatory Activities version 17.1.
Please refer to page A272 for declarations of interest in relation to abstract P154.